{
    "clinical_study": {
        "@rank": "463",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04345419"
        },
        "id_info": {
            "org_study_id": "COVID 19 treatment",
            "nct_id": "NCT04345419"
        },
        "brief_title": "A Real-life Experience on Treatment of Patients With COVID 19",
        "official_title": "The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tanta University",
                "agency_class": "Other"
            }
        },
        "source": "Tanta University",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide,\n      Ivermectin."
        },
        "detailed_description": {
            "textblock": "COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide,\n      Ivermectin on real life experience."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 15, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "December 2029"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "December 2029"
        },
        "phase": "Phase 2/Phase 3",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "Single (Participant)"
        },
        "primary_outcome": {
            "measure": "Number of patients with decreased viral load",
            "time_frame": "6 months",
            "description": "the estimated number of patients with decreased viral load"
        },
        "number_of_arms": "5",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "100"
        },
        "condition": "COVID",
        "arm_group": [
            {
                "arm_group_label": "Chloroquine",
                "arm_group_type": "Experimental",
                "description": "Chloroquine tablets"
            },
            {
                "arm_group_label": "Faviprevir",
                "arm_group_type": "Experimental",
                "description": "Faviprevir as antiviral treatment"
            },
            {
                "arm_group_label": "Nitazoxanide",
                "arm_group_type": "Experimental",
                "description": "Nitazoxanide treatment"
            },
            {
                "arm_group_label": "Ivermectin",
                "arm_group_type": "Experimental",
                "description": "Ivermectin treatment"
            },
            {
                "arm_group_label": "Niclosamide",
                "arm_group_type": "Experimental",
                "description": "Yomesan or niclosamide tablets"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Chloroquine",
                "description": "Chloroquine pills",
                "arm_group_label": "Chloroquine",
                "other_name": "Alexoquine"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Favipiravir",
                "description": "Favipiravir as antiviral drug",
                "arm_group_label": "Faviprevir",
                "other_name": "faviprevir"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Nitazoxanide",
                "description": "Nitazoxanide",
                "arm_group_label": "Nitazoxanide",
                "other_name": "alenia; nanazoxid"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Ivermectin",
                "description": "Ivermectin drug",
                "arm_group_label": "Ivermectin",
                "other_name": "ivactin"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Niclosamide",
                "description": "Yomesan or niclosamide tablets",
                "arm_group_label": "Niclosamide",
                "other_name": "Yomean, Niclosamide"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  COVID 19 patients\n\n        Exclusion Criteria:\n\n          -  allergy or contraindication to the drug"
            },
            "gender": "All",
            "minimum_age": "N/A",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": [
            {
                "last_name": "Sherief Abd-Elsalam, ass. prof.",
                "role": "Principal Investigator",
                "affiliation": "Tanta University Faculty of medicine"
            },
            {
                "last_name": "Eslam Saber, ass. lect",
                "role": "Study Director",
                "affiliation": "Tanta University Faculty of medicine"
            },
            {
                "last_name": "Mai Khalaf, ass. lect.",
                "role": "Study Chair",
                "affiliation": "Tanta University Faculty of medicine"
            }
        ],
        "overall_contact": {
            "last_name": "Sherief Abd-Elsalam",
            "phone": "+201147773440",
            "email": "sheriefabdelsalam@yahoo.com"
        },
        "location": {
            "facility": {
                "name": "Tanta university hospital",
                "address": {
                    "city": "Tanta",
                    "country": "Egypt"
                }
            }
        },
        "location_countries": {
            "country": "Egypt"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 11, 2020",
        "study_first_submitted_qc": "April 13, 2020",
        "study_first_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "last_update_submitted": "April 13, 2020",
        "last_update_submitted_qc": "April 13, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Tanta University",
            "investigator_full_name": "Sherief Abd-Elsalam",
            "investigator_title": "assistant professor of tropical medicine and infectious diseases"
        },
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine",
                "Chloroquine diphosphate",
                "Ivermectin",
                "Nitazoxanide",
                "Niclosamide"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}